Retraction Note to: Inhibition of microRNA miR-92a induces apoptosis and inhibits cell proliferation in human acute promyelocytic leukemia through modulation of p63 expression (Molecular Biology Reports, (2014), 41, 5, (2799-2808), 10.1007/s11033-014-3134-5);Inhibition of microRNA miR-92a induces apoptosis and inhibits cell proliferation in human acute promyelocytic leukemia through modulation of p63 expression

Molecular Biology Reports

Volumn 41, Issue 5, 2014, Pages 2799-2808

  Sharifi, Mohammadreza ^a   Salehi, Rasoul ^a   Gheisari, Yousof ^a   Kazemi, Mohammad ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute promyelocytic leukemia; Locked nucleic acid; MicroRNA; miR 92a; p63

Indexed keywords

ANTAGOMIR; MICRORNA; MICRORNA 92A; PROTEIN P63; UNCLASSIFIED DRUG; LOCKED NUCLEIC ACID; MIRN92 MICRORNA, HUMAN; OLIGONUCLEOTIDE; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; HL 60 CELL LINE; METABOLISM; NECROSIS; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICRORNAS; NECROSIS; OLIGONUCLEOTIDES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84905675888     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-019-04760-4     Document Type: Erratum

References (65)

1. Ruan K, Fang X, Ouyang G (2009) MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 285(2):116-126
2. Faller M, Guo F (2008) MicroRNA biogenesis: there's more than one way to skin a cat. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 1779(11):663-667
3. Reddy SDN, Gajula RP, Pakala SB, Kumar R (2010) MicroRNAs and cancer therapy. Cancer Biol Ther 9(7):479-482
4. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5):843-854 (Pubitemid 24014542)
5. Fabbri M, Garzon R, Andreeff M, Kantarjian H, Garcia-Manero G, Calin G (2008) MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia 22(6):1095-1105 (Pubitemid 351833775)
6. Rottiers V, Näär AM (2012) MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 13(4):239-250
7. Drummond MJ, McCarthy JJ, Sinha M, Spratt HM, Volpi E, Esser KA, Rasmussen BB (2011) Aging and microRNA expression in human skeletal muscle: a microarray and bioinformatics analysis. Physiol Genomics 43(10):595-603
8. Hu G, Drescher KM, Chen XM (2012) Exosomal miRNAs: biological properties and therapeutic potential. Front Genet 3:56
9. Barh D, Malhotra R, Ravi B, Sindhurani P (2010) Microrna let-7: an emerging next-generation cancer therapeutic. Current Oncology 17(1):70
10. Drakaki A, Iliopoulos D (2009) MicroRNA gene networks in oncogenesis. Curr Genomics 10(1):35
11. George G, Mittal RD (2010) MicroRNAs: potential biomarkers in cancer. Indian J Clin Biochem 25(1):4-14
12. Seto AG (2010) The road toward microRNA therapeutics. Int J Biochem Cell Biol 42(8):1298-1305
13. Gu J, Zhu X, Li Y, Dong D, Yao J, Lin C, Huang K, Hu H, Fei J (2011) miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines. Med Oncol 28(1):211-218
14. Chan E, Prado DE, Weidhaas JB (2011) Cancer microRNAs: from subtype profiling to predictors of response to therapy. Trends Mol Med. doi:10.1016/j.molmed.2011.01.008
15. Zhang P, Ma Y, Wang F, Yang J, Liu Z, Peng J, Qin H (2012) Comprehensive gene and microRNA expression profiling reveals the crucial role of hsa-let-7i and its target genes in colorectal cancer metastasis. Mol Biol Rep 39(2):1471-1478
16. Spizzo R, Rushworth D, Guerrero M, Calin GA (2009) RNA inhibition, microRNAs, and new therapeutic agents for cancer treatment. Clin Lymphoma Myeloma Leuk 9:313-318
17. Trang P, Weidhaas J, Slack F (2008) MicroRNAs as potential cancer therapeutics. Oncogene 27:S52-S57
18. Wang H, Lu H, Yang W, Luo C, Lu S, Zhou Y, Lin Y (2012) The influence of statin therapy on circulating microRNA-92a expression in patients with coronary heart disease. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 24(4):215 Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue
19. Baltimore DB (2012) MicroRNAs in Inflammation and their Disregulation in Cancer and Autoimmune Disease. Annual Review of Immunology 30 (1)
20. Estey EH (2012) Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87(1):89-99
21. Tallman MS (2008) Altman JK (2008) Curative strategies in acute promyelocytic leukemia. ASH Education Program Book 1:391-399
22. Wang ZY, Chen Z (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111(5):2505-2515
23. Breccia M, Latagliata R, Carmosino I, Cannella L, Diverio D, Guarini A, De Propris MS, Petti MC, Avvisati G, Cimino G (2008) Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin. Haematologica 93(12):1918-1920
24. Yang JJ, Park TS, Kim MJ, Cho EH, Oh SH, Jeon BR, Oh D, Huh JY, Marschalek R, Meyer C (2012) Acute promyelocytic leukemia with trisomy 8 showing normal PML-RARA FISH signal patterns: diagnostic application of long-distance polymerase chain reaction in molecularly discrepant leukemia cases. Annals of Hematology 91(10):1645-1648
25. Melnick A, Licht JD (1999) Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93(10):3167-3215 (Pubitemid 29220886)
26. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L (1990) All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results [see comments]. Blood 76(9):1704-1709
27. Mann G, Reinhardt D, Ritter J, Hermann J, Schmitt K, Gadner H, Creutzig U (2001) Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematol 80(7):417-422 (Pubitemid 32725460)
28. Tanaka M, Oikawa K, Takanashi M, Kudo M, Ohyashiki J, Ohyashiki K, Kuroda M (2009) Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 4(5):e5532
29. Ohyashiki JH, Umezu T, Kobayashi C, Hamamura RS, Tanaka M, Kuroda M, Ohyashiki K (2010) Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. BMC research notes 3(1):347
30. Manni I, Artuso S, Careccia S, Rizzo MG, Baserga R, Piaggio G, Sacchi A (2009) The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms. FASEB J 23(11):3957-3966
31. Van Haaften G, Agami R (2010) Tumorigenicity of the miR-17-92 cluster distilled. Genes Dev 24(1):1-4
32. Tanzer A, Stadler PF (2004) Molecular evolution of a microRNA cluster. J Mol Biol 339(2):327-335 (Pubitemid 38596952)
33. Alemdehy MF, Erkeland SJ (2012) MicroRNAs: key players of normal and malignant myelopoiesis. Curr Opin Hematol 19(4):261-267
34. Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU, Ganser A, Eder M, Scherr M (2007) Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood 109(10):4399-4405 (Pubitemid 46743409)
35. Hussein K, Büsche G, Muth M, Göhring G, Kreipe H, Bock O (2011) Expression of myelopoiesis-associated microRNA in bone marrow cells of atypical chronic myeloid leukaemia and chronic myelomonocytic leukaemia. Ann Hematol 90(3):307-313
36. Yoshizawa S, Ohyashiki J, Ohyashiki M, Umezu T, Suzuki K, Inagaki A, Iida S, Ohyashiki K (2012) Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J 2(1):e53
37. Ji M, Rao E, Ramachandrareddy H, Shen Y, Jiang C, Chen J, Hu Y, Rizzino A, Chan WC, Fu K (2011) The miR-17-92 microRNA cluster is regulated by multiple mechanisms in B-cell malignancies. Am J Pathol 179(4):1645-1656
38. Uziel T, Karginov FV, Xie S, Parker JS, Wang YD, Gajjar A, He L, Ellison D, Gilbertson RJ, Hannon G (2009) The miR-17-92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl Acad Sci 106(8):2812
39. Zhou T, Zhang G, Liu Z, Xia S, Tian H (2012) Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer. Int J Color Dis 28(1):19-24
40. Zhu L, Chen H, Zhou D, Li D, Bai R, Zheng S, Ge W (2012) MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility. Med Oncol 29(2):1037-1043
41. Saunders MA, Lim LP (2009) micro) Genomic medicine: microRNAs as therapeutics and biomarkers. RNA Biol 6(3):324
42. Dong C, Ji M, Ji C (2009) microRNAs and their potential target genes in leukemia pathogenesis. Cancer Biol Ther 8(3):200-205
43. Ørom UA, Kauppinen S, Lund AH (2006) LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 372:137-141
44. Elmén J, Lindow M, Schütz S, Lawrence M, Petri A, Obad S, Lindholm M, Hedtjärn M, Hansen HF, Berger U (2008) LNA-mediated microRNA silencing in non-human primates. Nature 452(7189):896-899 (Pubitemid 351550859)
45. Saito Y, Friedman JM, Chihara Y, Egger G, Chuang JC, Liang G (2009) Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochemical and biophysical research communications 379(3):726-731
46. Zhang H, Chen YQ (2009) New insight into the role of miRNAs in leukemia. Sci China, Ser C Life Sci 52(3):224-231
47. Veedu RN, Wengel J (2009) Locked nucleic acid as a novel class of therapeutic agents. RNA Biol 6(3):321-323
48. Sun S, Rockova V, Bullinger L, Dijkstra M, Döhner H, Löwenberg B, Jongen-Lavrencic M (2012) The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML. Leukemia. doi:10.1038/leu.2012.158
49. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, Chen P, Wang Y, Yan M, Qian Z (2008) Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci 105(40):15535-15540
50. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T (2008) MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111(6):3183-3189
51. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T (2005) A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 65(21):9628-9632 (Pubitemid 41541436)
52. Takakura S, Mitsutake N, Nakashima M, Namba H, Saenko VA, Rogounovitch TI, Nakazawa Y, Hayashi T, Ohtsuru A, Yamashita S (2008) Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci 99(6):1147-1154 (Pubitemid 351676626)
53. Humphreys KJ, Cobiac L, Le Leu RK, Van der Hoek MB, Michael MZ (2012) Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Mol Carcinog 52(6):459-474
54. Haug BH, Henriksen JR, Buechner J, Geerts D, Tømte E, Kogner P, Martinsson T, Flægstad T, Sveinbjørnsson B, Einvik C (2011) MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma. Carcinogenesis 32(7):1005-1012
55. Romilda C, Marika P, Alessandro S, Enrico L, Marina B, Andromachi K, Umberto C, Giacomo Z, Claudia M, Massimo R (2012) OxidativeDNAdamage correlates with cell immortalization andmir-92 expression in hepatocellular carcinoma. BMC Cancer 12(1):177
56. Mi S, Li Z, Chen P, He C, Cao D, Elkahloun A, Lu J, Pelloso LA, Wunderlich M, Huang H (2010) Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc Natl Acad Sci 107(8):3710-3715
57. Wong P, Iwasaki M, Somervaille TCP, Ficara F, Carico C, Arnold C, Chen CZ, Cleary ML (2010) The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res 70(9):3833-3842
58. Babashah S, Sadeghizadeh M, Tavirani MR, Farivar S, Soleimani M (2012) Aberrant microRNA expression and its implications in the pathogenesis of leukemias. Cellular Oncology 35(5):317-334
59. Yuan Y, Zeng ZY, Liu XH, Gong DJ, Tao J, Cheng HZ, Huang SD (2011) MicroRNA-203 inhibits cell proliferation by repressing DNp63 expression in human esophageal squamous cell carcinoma. BMC Cancer 11(1):57
60. Namløs HM, Meza-Zepeda LA, Barøy T, Østensen IHG, Kresse SH, Kuijjer ML, Serra M, Bürger H, Cleton-Jansen AM, Myklebost O (2012) Modulation of the osteosarcoma expression phenotype by MicroRNAs. PLoS One 7(10):e48086
61. Schee K, Boye K, Abrahamsen TW, Fodstad Ø;, Flatmark K (2012) Clinical relevance of microRNA mir-21, mir-31, mir-92a, mir-101, mir-106a and mir-145 in colorectal cancer. BMC Cancer 12(1):505
62. Tsuchida A, Ohno S, Wu W, Borjigin N, Fujita K, Aoki T, Ueda S, Takanashi M, Kuroda M (2011) miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer. Cancer Sci 102(12):2264-2271
63. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A, Burchfield J, Fox H, Doebele C, Ohtani K (2009) MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science Signalling 324(5935):1710
64. Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin MC (2009) Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res 15(20):6321-6326
65. Li Y, Zhu X, Gu J, Dong D, Yao J, Lin C, Huang K, Fei J (2010) Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Cancer Sci 101(4):948-954